Annual Clinical Quality Oversight Forum 2015

An effective quality oversight strategy is critical to the success of clinical trials. Ensuring compliance and maintaining inspection readiness has become increasingly complex as risk-based approaches for quality management are being adopted, increases in outsourcing have added to the number of stakeholders involved, and quality management systems are being implemented. This results in many challenges to ensure trial integrity by effectively assessing, optimizing and management the quality of clinical vendors and sites.

At ExL's 6th Clinical Quality Oversight Forum on October 5-7 in Philly, 30 of the industry's leading experts from small, mid and large sized companies, such as Vertex, Regeneron, UCB, Shire, Pfizer, Merck, Lilly, AbbVie, Alkermes, Teva, Nektar, Alexion and many more, candidly share their experiences on what's worked and what hasn't providing practical and applicable take-away strategies to improve your operations.

Featured topics include:

Identifying Clinical Quality Metrics
Achieving Inspection Readiness
Documenting Vendor Oversight
Risk-Based Monitoring
Implementing Quality Management Systems
Optimizing Data Quality
Executing Escalation Plans and Clinical CAPAs
Risk-Based Auditing

Join your peers at this comprehensive three-day event to learn, engage and network, and leave with the knowledge and connections to ensure GCP compliance.